| Julian N Anthony, MD | |
|
1955 Citracado Pkwy Ste 200, Escondido, CA 92029-4112 | |
| (760) 743-4789 | |
| (858) 673-5187 |
| Full Name | Julian N Anthony |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 27 Years |
| Location | 1955 Citracado Pkwy Ste 200, Escondido, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841392552 | NPI | - | NPPES |
| GR0100000 | Medicaid | CA | |
| ZZZ65165Z | Other | CA | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | A82316 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Palomar Health Downtown Campus | Escondido, CA | Hospital |
| Pomerado Hospital | Poway, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arch Health Partners Inc | 9931239027 | 221 |
News Archive
A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient's age and disease severity.
It's time to expand the models for blood pressure regulation, according to clinical pharmacologist Jens Titze, M.D. Titze and his colleagues have identified a new cast of cells and molecules that function in the skin to control sodium balance and blood pressure.
Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.
A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.
› Verified 6 days ago
| Entity Name | Emergency And Acute Care Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437103942 PECOS PAC ID: 9537108279 Enrollment ID: O20050502000734 |
News Archive
A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient's age and disease severity.
It's time to expand the models for blood pressure regulation, according to clinical pharmacologist Jens Titze, M.D. Titze and his colleagues have identified a new cast of cells and molecules that function in the skin to control sodium balance and blood pressure.
Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.
A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.
› Verified 6 days ago
| Entity Name | Arch Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649500141 PECOS PAC ID: 9931239027 Enrollment ID: O20100616000715 |
News Archive
A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient's age and disease severity.
It's time to expand the models for blood pressure regulation, according to clinical pharmacologist Jens Titze, M.D. Titze and his colleagues have identified a new cast of cells and molecules that function in the skin to control sodium balance and blood pressure.
Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.
A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julian N Anthony, MD Po Box 25100, Fresno, CA 93729-5100 Ph: (559) 326-1222 | Julian N Anthony, MD 1955 Citracado Pkwy Ste 200, Escondido, CA 92029-4112 Ph: (760) 743-4789 |
News Archive
A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient's age and disease severity.
It's time to expand the models for blood pressure regulation, according to clinical pharmacologist Jens Titze, M.D. Titze and his colleagues have identified a new cast of cells and molecules that function in the skin to control sodium balance and blood pressure.
Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.
A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.
› Verified 6 days ago
Paul Victor Polishuk, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 215 S Hickory St, Suite 114, Escondido, CA 92025 Phone: 760-743-5111 Fax: 858-429-7934 | |
Dr. Philip C Bosch, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 651 E Pennsylvania Ave, Ste 201, Escondido, CA 92025 Phone: 760-743-3135 Fax: 760-743-7424 | |
Dr. Thomas Allyn Jones, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 215 S Hickory St, Suite 114, Escondido, CA 92025 Phone: 760-743-5111 Fax: 858-429-7934 | |
Dr. Snaford Behrens, MD Urology Medicare: Medicare Enrolled Practice Location: 255 N Elm St, Escondido, CA 92025 Phone: 858-245-3368 |